The purpose of this article is to provide advanced practitioners with important information about new treatment options for mantle cell lymphoma and chronic lymphocytic leukemia, including novel oral agents, management of related side effects, and patient education. REVIEW IBRUTINIB IN MCL and CLL 421 CE Learning Objectives After completing this educational activity, participants should be able to: 1. Identify clinical features and considerations to determine which patients are eligible for treatment with ibrutinib REVIEW McNALLY et al.